lose weight | |||||
NEWS | |||||
Pemvidutide, a New Weight Loss Drug, Hopes to Take on Ozempic - Everyday Health Now in clinical trials, this new medication can lead to impressive weight loss while preserving more lean muscle than its rivals.
| |||||
New drug tirzepatide significantly improves sleep apnea and weight loss - News-Medical The effects of tirzepatide on adults with obesity and moderate-to-severe obstructive sleep apnea.
| |||||
Semaglutide and Greater Weight Loss in Women Than Men With Obesity-Related HFpEF A study has found that, in patients with obesity-related HFpEF, women receiving semaglutide experience weight loss to a greater extent than men.
| |||||
Does Ozempic boost fertility? What the science says - Nature Blockbuster weight-loss drugs have been linked to unexplained pregnancies. Research shows it is plausible, but more data is needed.
| |||||
Nestlé Health Science unveils GLP-1 nutrition support platform | Drug Store News Preserving Lean Muscle Mass: GLP-1 therapy, while aiding in weight loss, may lead to the loss of lean muscle mass due to a decrease in nutritional ...
| |||||
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial Rationale and ... Weight loss approaches that involve dieting, bariatric surgery and GLP-1 agonists work by decreasing energy intake rather than by increasing energy ...
| |||||
Novo Nordisk says weight-loss drug Wegovy approved in China - Medical Xpress Novo Nordisk's flagship weight-loss drug Wegovy has been approved for use in China, the Danish pharmaceutical giant said.
| |||||
Does cycling have a (weight-loss) drug problem? - Escape Collective Does cycling have a (weight-loss) drug problem? Are drugs like Ozempic being used by cyclists? And should they be? Alan McCubbin. by ...
| |||||
WEB | |||||
Newborn Weight Loss Tool What is it? "Newt is the first tool that allows pediatric healthcare providers and parents to see how a newborn's weight during the first days and ...
| |||||
See more results | Edit this alert |
You have received this email because you have subscribed to Google Alerts. |
Receive this alert as RSS feed |
Send Feedback |